|
US6025154A
(en)
|
1995-06-06 |
2000-02-15 |
Human Genome Sciences, Inc. |
Polynucleotides encoding human G-protein chemokine receptor HDGNR10
|
|
US7368111B2
(en)
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
|
AU5087799A
(en)
|
1998-07-06 |
2000-01-24 |
Beth Israel Deaconess Medical Center |
Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
|
|
ID30316A
(id)
*
|
1999-04-09 |
2001-11-22 |
Hanmi Pharma Co Ltd |
METODE UNTUK MENGHITUNG FAKTOR-β1 PERUBAHAN PERTUMBUHAN DAN METODE UNTUK MENDETEKSI KANKER DENGAN FAKTOR-β1 PERUBAHAN PERTUMBUHAN
|
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
|
EP1486560A3
(en)
*
|
1999-04-30 |
2005-02-09 |
Cambridge Antibody Technology LTD |
Specific antibodies and antibody fragments for TGFBETA1
|
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
|
US20040001826A1
(en)
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
|
WO2001027621A2
(en)
*
|
1999-10-07 |
2001-04-19 |
Pharmacia Corporation |
Competitive inhibition elisa for antibody detection
|
|
SE9903895D0
(sv)
*
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
|
AU2001268427B2
(en)
|
2000-06-16 |
2007-03-29 |
Glaxosmithkline Intellectual Property Limited |
Antibodies that immunospecifically bind to blys
|
|
EP2412384A1
(en)
|
2000-11-28 |
2012-02-01 |
MedImmune, LLC |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US20020151695A1
(en)
*
|
2000-11-28 |
2002-10-17 |
Shuqian Jing |
Transforming growth factor-beta-related molecules and uses thereof
|
|
JP2005503116A
(ja)
*
|
2001-02-09 |
2005-02-03 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
|
|
US7175988B2
(en)
|
2001-02-09 |
2007-02-13 |
Human Genome Sciences, Inc. |
Human G-protein Chemokine Receptor (CCR5) HDGNR10
|
|
CA2444632A1
(en)
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
|
MXPA03010747A
(es)
|
2001-05-25 |
2004-03-02 |
Human Genome Sciences Inc |
Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
|
|
US7393934B2
(en)
|
2001-12-21 |
2008-07-01 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor (CCR5) HDGNR10
|
|
WO2003104428A2
(en)
|
2002-01-21 |
2003-12-18 |
Vaccinex, Inc. |
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
|
|
DE10210427A1
(de)
|
2002-03-09 |
2003-10-09 |
Hans Konrad Mueller-Hermelink |
Humaner monoklonaler Antikörper
|
|
US7371383B2
(en)
|
2002-04-12 |
2008-05-13 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
EP1521776A2
(en)
|
2002-07-04 |
2005-04-13 |
Oncomab Gmbh |
Neoplasm specific antibodies and uses thereof
|
|
SI2301965T1
(sl)
|
2002-10-16 |
2015-07-31 |
Purdue Pharma L.P. |
Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh
|
|
GB0224436D0
(en)
*
|
2002-10-21 |
2002-11-27 |
Univ Cambridge Tech |
Polypetides methods and means
|
|
CN1753912B
(zh)
*
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
DE10311248A1
(de)
|
2003-03-14 |
2004-09-30 |
Müller-Hermelink, Hans Konrad, Prof. Dr. |
Humaner monoklonaler Antikörper
|
|
JP4764818B2
(ja)
|
2003-04-11 |
2011-09-07 |
メディミューン，エルエルシー |
組換えｉｌ−９抗体およびその使用
|
|
CN101039957A
(zh)
|
2003-05-16 |
2007-09-19 |
因特缪恩公司 |
合成的趋化因子受体配体及其使用方法
|
|
WO2005010049A2
(en)
*
|
2003-07-09 |
2005-02-03 |
Eli Lilly And Company |
Tgf-beta1 ligands
|
|
EP1644408A1
(en)
|
2003-07-15 |
2006-04-12 |
Barros Research Institute |
Eimeria tenella antigen for immunotherapy of coccidiosis
|
|
EP1648935A2
(en)
*
|
2003-07-25 |
2006-04-26 |
Amgen Inc. |
Antagonists and agonists of ldcam and methods of use
|
|
EP1668111A4
(en)
|
2003-08-08 |
2008-07-02 |
Genenews Inc |
OSTEOARTHRITIS BIOMARKERS AND USES THEREOF
|
|
DE10353175A1
(de)
|
2003-11-14 |
2005-06-16 |
Müller-Hermelink, Hans Konrad, Prof. Dr. |
Humaner monoklonaler Antikörper mit fettsenkender Wirkung
|
|
EP1531162A1
(en)
|
2003-11-14 |
2005-05-18 |
Heinz Vollmers |
Adenocarcinoma specific antibody SAM-6, and uses thereof
|
|
WO2005105841A2
(en)
|
2004-03-12 |
2005-11-10 |
Human Genome Sciences, Inc. |
Human g-protein chemokine receptor (ccr5) hdgnr10
|
|
CN1961003B
(zh)
|
2004-03-31 |
2013-03-27 |
健泰科生物技术公司 |
人源化抗TGF-β抗体
|
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
|
WO2006034292A2
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
|
US20060121042A1
(en)
|
2004-10-27 |
2006-06-08 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
|
US7713695B2
(en)
|
2005-02-07 |
2010-05-11 |
Genenews, Inc. |
Mild osteoarthritis biomarkers and uses thereof
|
|
WO2006086469A2
(en)
|
2005-02-08 |
2006-08-17 |
Genzyme Corporation |
Antibodies to tgfbeta
|
|
KR101335798B1
(ko)
|
2005-02-15 |
2013-12-02 |
듀크 유니버시티 |
항-ｃｄ19 항체 및 종양학에서 이의 용도
|
|
US8211430B2
(en)
|
2005-03-04 |
2012-07-03 |
Curedm Group Holdings, Llc |
Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
|
|
ATE505489T1
(de)
|
2005-04-22 |
2011-04-15 |
Lilly Co Eli |
Tgf-beta-1-spezifische antikörper
|
|
CA2607281C
(en)
|
2005-05-05 |
2023-10-03 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
|
EP1883417A2
(en)
|
2005-05-25 |
2008-02-06 |
Curedm Inc. |
Peptides, derivatives and analogs thereof, and methods of using same
|
|
EP1893647A2
(en)
|
2005-06-23 |
2008-03-05 |
MedImmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
|
AU2006304883A1
(en)
|
2005-10-21 |
2007-04-26 |
Genenews Inc. |
Method and apparatus for correlating levels of biomarker products with disease
|
|
EP1948675B1
(en)
|
2005-10-25 |
2014-07-30 |
The Johns Hopkins University |
Methods and compositions for the treatment of marfan syndrome and associated disorders
|
|
EP2650306A1
(en)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
US8454952B2
(en)
|
2006-03-13 |
2013-06-04 |
The Johns Hopkins University |
Augmentation of endothelial thromboresistance
|
|
SG10201504662WA
(en)
|
2006-06-14 |
2015-07-30 |
Macrogenics Inc |
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
|
|
ES2439994T3
(es)
|
2006-08-28 |
2014-01-27 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
|
|
DK2083863T3
(da)
|
2006-10-03 |
2015-06-22 |
Genzyme Corp |
Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
|
|
WO2008064306A2
(en)
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
|
EP2687232A1
(en)
|
2006-12-06 |
2014-01-22 |
MedImmune, LLC |
Methods of treating systemic lupus erythematosus
|
|
CA2682292A1
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Llc |
Aqueous formulation comprising an anti-human interferon alpha antibody
|
|
EP2068925A4
(en)
|
2007-05-07 |
2011-08-31 |
Medimmune Llc |
ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
|
|
HUE036885T2
(hu)
|
2007-05-14 |
2018-08-28 |
Astrazeneca Ab |
Eljárás a bazofil-szint csökkentésére
|
|
EA201000399A1
(ru)
|
2007-08-30 |
2011-02-28 |
Кьюрдм, Инк. |
Композиции и способы использования проостровковых пептидов и их аналогов
|
|
PT2219452E
(pt)
|
2007-11-05 |
2016-01-26 |
Medimmune Llc |
Métodos de tratamento de esclerodermia
|
|
US9308257B2
(en)
|
2007-11-28 |
2016-04-12 |
Medimmune, Llc |
Protein formulation
|
|
JP2011509675A
(ja)
|
2008-01-18 |
2011-03-31 |
メディミューン，エルエルシー |
部位特異的コンジュゲーションのためのシステイン操作抗体
|
|
HRP20160855T1
(hr)
|
2008-02-08 |
2016-09-23 |
Medimmune, Llc |
Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
|
|
KR101682257B1
(ko)
|
2008-10-31 |
2016-12-05 |
도레이 카부시키가이샤 |
인간 ｃｘｃｌ１ 단백질의 면역학적 측정 방법
|
|
JP5933975B2
(ja)
|
2008-11-12 |
2016-06-15 |
メディミューン，エルエルシー |
抗体製剤
|
|
WO2010082134A1
(en)
|
2009-01-14 |
2010-07-22 |
Iq Therapeutics Bv |
Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
|
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
|
AU2010270979B2
(en)
|
2009-06-22 |
2015-04-23 |
Medimmune, Llc |
Engineered Fc regions for site-specific conjugation
|
|
PL2464664T3
(pl)
|
2009-08-13 |
2016-02-29 |
Crucell Holland Bv |
Przeciwciała przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (RSV) i sposoby zastosowania
|
|
EP2496243A2
(en)
|
2009-11-04 |
2012-09-12 |
Erasmus University Medical Center Rotterdam |
Novel compounds for modulating neovascularisation and methods of treatment using these compounds
|
|
ME02464B
(me)
|
2010-03-12 |
2017-02-20 |
Genzyme Corp |
Kombinovana terapija za lečenje raka dojke
|
|
PH12012502244A1
(en)
|
2010-07-09 |
2016-09-30 |
Crucell Holland Bv |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
|
CA2823154A1
(en)
|
2010-12-27 |
2012-07-05 |
Lsip, Llc |
Ips cells and method for generating same
|
|
US9540443B2
(en)
|
2011-01-26 |
2017-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies
|
|
US20140308275A1
(en)
|
2011-07-27 |
2014-10-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale |
Methods for diagnosing and treating myhre syndrome
|
|
WO2013062544A1
(en)
|
2011-10-26 |
2013-05-02 |
Seattle Children's Research Institute |
Cysteamine in the treatment of fibrotic disease
|
|
WO2013078286A1
(en)
|
2011-11-22 |
2013-05-30 |
Cornell University |
Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling
|
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
|
EP2799537B1
(en)
|
2011-12-28 |
2021-09-22 |
Kyoto Prefectural Public University Corporation |
Normalization of culture of corneal endothelial cells
|
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
PL2953634T3
(pl)
|
2013-02-07 |
2021-11-22 |
The General Hospital Corporation |
Sposoby namnażania lub zubożania limfocytów t-regulatorowych
|
|
WO2014129895A1
(en)
|
2013-02-19 |
2014-08-28 |
Stichting Vu-Vumc |
Means and method for increasing the sensitivity of cancers for radiotherapy
|
|
PT2971048T
(pt)
*
|
2013-03-11 |
2019-02-06 |
Genzyme Corp |
Anticorpos anti-tgf-beta manipulados e fragmentos de ligação a antigénios
|
|
LT2970890T
(lt)
|
2013-03-14 |
2020-07-10 |
The Brigham And Women`S Hospital, Inc. |
Kompozicijos ir būdai, skirti epitelinių kamieninių ląstelių padauginimui ir kultivavimui
|
|
SG11201509982UA
(https=)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
|
WO2014200349A1
(en)
|
2013-06-13 |
2014-12-18 |
Fast Forward Pharmaceutical B.V. |
Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
|
|
KR102313341B1
(ko)
|
2013-08-26 |
2021-10-18 |
바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 |
시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
|
|
CA2925099C
(en)
|
2013-10-01 |
2023-04-04 |
Toray Industries, Inc. |
Method for detecting pancreatic tumor, antibodies, and kit for the detection of pancreatic tumor
|
|
CA2927898C
(en)
|
2013-10-31 |
2021-11-16 |
Kyoto Prefectural Public University Corporation |
Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
SG10201912986PA
(en)
|
2014-05-28 |
2020-02-27 |
Agenus Inc |
Anti-gitr antibodies and methods of use thereof
|
|
DK3154583T3
(da)
|
2014-06-04 |
2021-03-22 |
Biontech Res And Development Inc |
Humane monoklonale antistoffer mod gangliosid gd2
|
|
WO2016037016A1
(en)
|
2014-09-03 |
2016-03-10 |
The Brigham And Women's Hospital, Inc. |
Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
|
|
CN106715473B
(zh)
|
2014-10-01 |
2021-11-23 |
免疫医疗有限公司 |
替格瑞洛的抗体及其使用方法
|
|
PL3333191T3
(pl)
|
2014-12-11 |
2021-05-04 |
Pierre Fabre Médicament |
Przeciwciała przeciwko c10orf54 i ich zastosowania
|
|
JP7211703B2
(ja)
|
2014-12-22 |
2023-01-24 |
ザ ロックフェラー ユニバーシティー |
抗ｍｅｒｔｋアゴニスト抗体及びその使用
|
|
EP3252474B1
(en)
|
2015-01-26 |
2020-10-21 |
Toray Industries, Inc. |
Method and kit for detecting biliary tract cancer
|
|
JP6797107B2
(ja)
|
2015-03-02 |
2020-12-09 |
東レ株式会社 |
膵臓機能異常の検出方法及び検出用キット
|
|
MX2017011194A
(es)
|
2015-03-03 |
2018-04-10 |
Kymab Ltd |
Anticuerpos, usos y métodos.
|
|
CA2984794A1
(en)
|
2015-05-07 |
2016-11-10 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
|
EP3294773A1
(en)
*
|
2015-05-15 |
2018-03-21 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
|
US10882903B2
(en)
|
2015-05-18 |
2021-01-05 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Methods and compositions for treating an alphavirus infection
|
|
MA44594B1
(fr)
|
2015-05-29 |
2020-09-30 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
|
|
WO2017040312A1
(en)
|
2015-08-28 |
2017-03-09 |
The General Hospital Corporation |
Agonistic anti-tumor necrosis factor receptor 2 antibodies
|
|
CN114605548A
(zh)
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
|
CN108779437A
(zh)
|
2016-01-08 |
2018-11-09 |
麻省理工学院 |
分化的肠内分泌细胞和胰岛素产生细胞的制备
|
|
JP2019511911A
(ja)
*
|
2016-02-17 |
2019-05-09 |
ノバルティス アーゲー |
Ｔｇｆベータ２抗体
|
|
US10201540B2
(en)
|
2016-03-02 |
2019-02-12 |
Frequency Therapeutics, Inc. |
Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
|
|
US11260130B2
(en)
|
2016-03-02 |
2022-03-01 |
Frequency Therapeutics, Inc. |
Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
|
|
US10213511B2
(en)
|
2016-03-02 |
2019-02-26 |
Frequency Therapeutics, Inc. |
Thermoreversible compositions for administration of therapeutic agents
|
|
WO2017156500A1
(en)
*
|
2016-03-11 |
2017-09-14 |
Scholar Rock, Inc. |
Tgfb1-binding immunoglobulins and use thereof
|
|
CA3023930C
(en)
|
2016-05-13 |
2025-09-23 |
The General Hospital Corporation |
TUMOR-ANTAGONISTIC ANTIBODIES OF THE NECROSIS FACTOR RECEPTOR SUPERFAMILY
|
|
WO2017201036A1
(en)
|
2016-05-17 |
2017-11-23 |
Genentech, Inc. |
Stromal gene signatures for diagnosis and use in immunotherapy
|
|
TWI781934B
(zh)
|
2016-05-27 |
2022-11-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
AU2017292184A1
(en)
|
2016-07-08 |
2019-02-07 |
Staten Biotechnology B.V. |
Anti-Apoc3 antibodies and methods of use thereof
|
|
SG10201912663YA
(en)
|
2016-10-11 |
2020-03-30 |
Agenus Inc |
Anti-lag-3 antibodies and methods of use thereof
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
WO2018083538A1
(en)
|
2016-11-07 |
2018-05-11 |
Neuracle Scienc3 Co., Ltd. |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
|
WO2018106862A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
|
JP7106538B2
(ja)
|
2016-12-07 |
2022-07-26 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
|
US11066419B2
(en)
|
2016-12-30 |
2021-07-20 |
Frequency Therapeutics, Inc. |
1H-pyrrole-2,5-dione compounds and methods of using same
|
|
TWI788321B
(zh)
|
2017-01-20 |
2023-01-01 |
美商健臻公司 |
骨靶向抗體
|
|
TW202506185A
(zh)
|
2017-01-20 |
2025-02-16 |
法商賽諾菲公司 |
抗TGF-β抗體及其用途
|
|
JP7297672B2
(ja)
|
2017-04-13 |
2023-06-26 |
アジェナス インコーポレイテッド |
抗ｃｄ１３７抗体およびその使用方法
|
|
JP2020517242A
(ja)
|
2017-04-21 |
2020-06-18 |
スターテン・バイオテクノロジー・ベー・フェー |
抗ＡｐｏＣ３抗体およびその使用方法
|
|
RS64576B1
(sr)
|
2017-05-01 |
2023-10-31 |
Agenus Inc |
Anti-tigit antitela i postupci njihove primene
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
JP7076059B2
(ja)
|
2017-06-27 |
2022-05-27 |
ニューラクル サイエンス カンパニー リミテッド |
抗ｆａｍ１９ａ５抗体及びその用途
|
|
EP3672990A1
(en)
|
2017-08-25 |
2020-07-01 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
|
US11707522B2
(en)
|
2017-10-13 |
2023-07-25 |
Boehringer Ingelheim International Gmbh |
Human antibodies to Tn antigen
|
|
KR20200074975A
(ko)
|
2017-10-31 |
2020-06-25 |
스태튼 바이오테크놀로지 비.브이. |
항-ApoC3 항체 및 이의 사용 방법
|
|
ES2984919T3
(es)
|
2017-11-06 |
2024-10-31 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
|
MX2020005473A
(es)
|
2017-11-27 |
2020-08-27 |
Purdue Pharma Lp |
Anticuerpos humanizados que se dirigen al factor tisular humano.
|
|
JP2021514379A
(ja)
|
2018-02-21 |
2021-06-10 |
ファイブ プライム セラピューティクス， インコーポレイテッド |
Ｂ７−ｈ４抗体製剤
|
|
MA52416A
(fr)
|
2018-03-02 |
2021-04-21 |
Five Prime Therapeutics Inc |
Anticorps b7-h4 et leurs procédés d'utilisation
|
|
CA3098805A1
(en)
|
2018-05-10 |
2019-11-14 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
|
US12006357B2
(en)
|
2018-06-26 |
2024-06-11 |
Mor Research Applications Ltd. |
Transthyretin antibodies and uses thereof
|
|
KR102767692B1
(ko)
|
2018-07-20 |
2025-02-17 |
피에르 파브르 메디카먼트 |
Vista의 수용체
|
|
CN113195707A
(zh)
|
2018-08-17 |
2021-07-30 |
频率治疗公司 |
用于通过上调jag-1来生成毛细胞的组合物和方法
|
|
WO2020037215A1
(en)
|
2018-08-17 |
2020-02-20 |
Icahn School Of Medicine At Mount Sinai |
Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
|
|
US11617745B2
(en)
|
2018-08-17 |
2023-04-04 |
Frequency Therapeutics, Inc. |
Compositions and methods for generating hair cells by downregulating FOXO
|
|
EP3856773A1
(en)
|
2018-09-28 |
2021-08-04 |
Kyowa Kirin Co., Ltd. |
Il-36 antibodies and uses thereof
|
|
WO2020070678A2
(en)
|
2018-10-03 |
2020-04-09 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
|
|
CN113302205B
(zh)
|
2018-11-15 |
2024-12-06 |
综合医院公司 |
激动性肿瘤坏死因子受体超家族多肽
|
|
US12234292B2
(en)
|
2018-12-20 |
2025-02-25 |
Kyowa Kirin Co., Ltd. |
FN14 antibodies and uses thereof
|
|
CA3117619A1
(en)
|
2019-01-02 |
2020-07-09 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
|
MA55080A
(fr)
|
2019-02-26 |
2022-01-05 |
Inspirna Inc |
Anticorps anti-mertk à affinité élevée et utilisations associées
|
|
CN113874392B
(zh)
|
2019-03-28 |
2025-10-21 |
丹尼斯科美国公司 |
工程化抗体
|
|
JP2022527972A
(ja)
|
2019-04-02 |
2022-06-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
前悪性病変を有する患者において癌を予測及び予防する方法
|
|
CN114867751B
(zh)
|
2019-08-12 |
2024-11-29 |
阿帕特夫研究和发展有限公司 |
4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体
|
|
TW202122420A
(zh)
|
2019-08-30 |
2021-06-16 |
美商艾吉納斯公司 |
抗ｃｄ９６抗體及其使用方法
|
|
US20220306736A1
(en)
|
2019-09-04 |
2022-09-29 |
Y-Biologics Inc. |
Anti-vsig4 antibody or antigen binding fragment and uses thereof
|
|
CN112852738B
(zh)
*
|
2019-11-27 |
2023-02-28 |
四川省肿瘤医院 |
一种前列腺癌细胞膜片的制备方法
|
|
JP2023513834A
(ja)
|
2020-02-18 |
2023-04-03 |
アレクトル エルエルシー |
Ｐｉｌｒａ抗体及びその使用方法
|
|
US20230235073A1
(en)
|
2020-03-06 |
2023-07-27 |
Ona Therapeutics, S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
|
FI4045533T3
(fi)
|
2020-03-26 |
2024-02-02 |
Univ Vanderbilt |
Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
|
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
|
AU2021275361A1
(en)
|
2020-05-17 |
2023-01-19 |
Astrazeneca Uk Limited |
SARS-CoV-2 antibodies and methods of selecting and using the same
|
|
AU2021313348A1
(en)
|
2020-07-20 |
2023-03-09 |
Astrazeneca Uk Limited |
SARS-CoV-2 proteins, anti-SARS-CoV-2 antibodies, and methods of using the same
|
|
US11725052B2
(en)
|
2020-08-18 |
2023-08-15 |
Cephalon Llc |
Anti-PAR-2 antibodies and methods of use thereof
|
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
|
US20240301086A1
(en)
|
2020-12-01 |
2024-09-12 |
Aptevo Research And Development Llc |
Tumor-associated antigens and cd3-binding proteins, related compositions, and methods
|
|
US20240158503A1
(en)
|
2021-03-03 |
2024-05-16 |
Pierre Fabre Medicament |
Anti-vsig4 antibody or antigen binding fragment and uses thereof
|
|
CA3214633A1
(en)
|
2021-03-24 |
2022-09-29 |
Toray Industries, Inc. |
Method and kit for assisting in determination of malignant pancreatic cystic tumor
|
|
CA3220629A1
(en)
|
2021-05-28 |
2022-12-01 |
Tobin J. CAMMETT |
Methods for detecting cm-tma biomarkers
|
|
JP2024522213A
(ja)
|
2021-06-14 |
2024-06-11 |
アルジェニクス ビーブイ |
抗ｉｌ－９抗体及びその使用方法
|
|
AU2022320051A1
(en)
|
2021-07-30 |
2024-01-25 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
|
TW202342510A
(zh)
|
2022-02-18 |
2023-11-01 |
英商Ｒｑ生物科技有限公司 |
抗體
|
|
WO2023192436A1
(en)
|
2022-03-31 |
2023-10-05 |
Alexion Pharmaceuticals, Inc. |
Singleplex or multiplexed assay for complement markers in fresh biological samples
|
|
JP2025514858A
(ja)
|
2022-04-29 |
2025-05-09 |
アストラゼネカ・ユーケイ・リミテッド |
ＳＡＲＳ－ＣｏＶ－２抗体、及びその使用方法
|
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
|
CA3262035A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
BIOLOGICALLY ENGINEERED IMPROVED MATERIAL AND PAIRING METHODS FOR VARIABLE ANTIGEN-BINDING REGIONS
|
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
|
CN120035450A
(zh)
|
2022-09-06 |
2025-05-23 |
阿雷克森制药公司 |
造血干细胞移植物相关血栓性微血管病（hsct-tma）患者的诊断和预后生物标志物谱
|
|
WO2024077095A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating bladder cancer
|
|
WO2024077166A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating lung cancer
|
|
WO2024194686A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
AU2024277678A1
(en)
|
2023-05-25 |
2025-11-27 |
Dispatch Biotherapeutics, Inc. |
Synthetic cancer antigens as targets for treating cancers
|
|
US20250109187A1
(en)
|
2023-09-28 |
2025-04-03 |
Novavax, Inc. |
ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
|
|
WO2025133707A1
(en)
|
2023-12-19 |
2025-06-26 |
Vectory Therapeutics B.V. |
Anti-tdp-43 antibodies and uses thereof
|
|
WO2025171388A1
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens with modified domains and related methods and uses
|
|
WO2025171383A2
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens and related methods and uses
|
|
US20250361297A1
(en)
|
2024-03-12 |
2025-11-27 |
Adaptam Therapeutics, S.L. |
Anti- siglec-15 binding molecules and methods of use
|